{"id":779586,"date":"2023-08-23T08:22:29","date_gmt":"2023-08-23T12:22:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-ranks-first-in-overall-corporate-reputation-by-rare-disease-patient-advocacy-groups\/"},"modified":"2023-08-23T08:22:29","modified_gmt":"2023-08-23T12:22:29","slug":"horizon-therapeutics-plc-ranks-first-in-overall-corporate-reputation-by-rare-disease-patient-advocacy-groups","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-ranks-first-in-overall-corporate-reputation-by-rare-disease-patient-advocacy-groups\/","title":{"rendered":"Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups"},"content":{"rendered":"

<\/p>\n

Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups<\/b><\/p>\n

DUBLIN–(BUSINESS WIRE<\/a>)–
\nHorizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company. Rare disease patient groups who worked with Horizon also ranked the company first in 10 of the 14 indicators including patient centricity, patient information, integrity, access to medicines, relationships (communications, long-term support and ease of working) and services \u201cbeyond the pill.\u201d The results are based on PatientView\u2019s 2022 global \u201cCorporate Reputation of Pharma\u201d survey of 426 patient groups who evaluated 34 pharmaceutical and biotechnology companies.<\/p>\n

\n\u201cWe are honored by the feedback that rare disease patient advocacy groups provided within the PatientView report,\u201d said Matt Flesch, vice president, patient advocacy and product communications, Horizon. \u201cOur approach to patient advocacy is to participate, listen and learn, knowing that rare disease patient groups are usually the main catalyst for progress, driving awareness and education, building community and advancing research toward treatments and cures. From the programs that we support to the initiatives that we create; our belief is that meaningful and appropriate collaboration with patient advocacy groups is core to all our work at Horizon.\u201d<\/p>\n

\nIn the PatientView report summarizing survey results from rare disease groups, 91 rare disease patient advocacy groups said they were familiar with Horizon and 59 said they worked with the company. Fifty-six percent of groups familiar with Horizon were from the United States, with the rest headquartered in other areas around the world \u2013 reflecting Horizon\u2019s recent global expansion as well as its approach to supporting a wide range of patient advocacy organizations.<\/p>\n

\nIn previous PatientView results released in the first half of 2023<\/a>, Horizon ranked second in overall corporate reputation and first in patient centricity and integrity among all patient advocacy groups around the world who worked with the company (not just rare disease groups), and first in overall corporate reputation among patient advocacy groups in the United States.<\/p>\n

\nSelect highlights from 2022 advocacy engagement and collaboration include:<\/p>\n